MK-3475 Immunotherapy in Endometrial Carcinoma

Summary

Due to the high expression of PD-L1 in endometrial cancers as well as in ovarian cancers which are molecularly similar to uterine serous cancers, using pembrolizumab should be beneficial in this patient population. Since the investigators are able to get a pre-treatment research- related endometrial biopsy as well as the surgical specimen post two cycles of pembrolizumab, the investigators will be able to evaluate the mechanism of action of this drug on the endometrial cancer tumor environment.

Timeline

Start

2016-02-05

Primary completion

2019-01-01

Completion

2020-10-03

Drugs

Indications